Submitted by Anonymous (not verified) on 21 November 2023 - 11:56
Human medicines European public assessment report (EPAR): Respreeza, alpha1-proteinase inhibitor (human), Genetic Diseases, Inborn;Lung Diseases, Date of authorisation: 20/08/2015, Revision: 12, Status: Authorised
Source: